Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.12 USD

96.12
370,120

+0.08 (0.08%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Henry Schein (HSIC) Hits New 52-Week High: What's Driving It?

Henry Schein (HSIC) is optimistic about maintaining robust sales of PPE and COVID-19-related products.

Amedisys (AMED) Q1 Earnings Beat Estimates, 2021 View Up

Amedisys' (AMED) first-quarter 2021 revenues improves year over year on solid growth in the Home Health and Hospice divisions.

Amedisys (AMED) to Report Q1 Earnings: What's in Store?

Growth in Home Health and Hospice along with recent innovation and acquisitions is expected to have contributed to Amedisys (AMED) top-line growth in Q1.

The Zacks Analyst Blog Highlights: Addus HomeCare, LHC Group and Amedisys

The Zacks Analyst Blog Highlights: Addus HomeCare, LHC Group and Amedisys

Sapna Bagaria headshot

Biden Chips in $400B for Home Healthcare: Stocks to Watch

Biden's support to expand access to long-term care services under Medicaid bodes well for companies providing home healthcare.

Why Is Amedisys (AMED) Up 1.8% Since Last Earnings Report?

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss

Amedisys (AMED) fourth-quarter 2020 revenues improve year over year, driven by strong growth across the Home Health and Hospice divisions.

Is a Surprise Coming for Amedisys (AMED) This Earnings Season?

Amedisys (AMED) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Higher Business Volumes Aid Teladoc (TDOC) Q4 Earnings?

Teladoc Health's (TDOC) Q4 earnings are likely to reflect higher visit volumes and subscriptions, along with an increase in marketing expenses.

Amedisys (AMED) Earnings Expected to Grow: Should You Buy?

Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Amedisys (AMED) Keep the Earnings Surprise Streak Alive?

Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Amedisys (AMED) to Report Q4 Results: Wall Street Expects Earnings Growth

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Varian (VAR) Q1 Earnings Beat Estimates, Revenues Miss Mark

Varian's (VAR) receipt of 13 Ethos orders in fiscal Q1 raises investors' optimism on the stock.

Encompass Health (EHC) Steadily Grows Inpatient Rehab Business

Encompass Health (EHC) is continuously investing in post acute care services, which are in huge demand in the United States.

Sriparna Ghosal headshot

3 Biggest MedTech Trends to Watch in 2021 for Better Returns

Following are the three MedTech trends, which showed a steady momentum through the pandemic year and are likely to sustain even after the economic mayhem subsides.

Abbott (ABT) to Expand in Booming TBI Space on New Approval

If positive, Abbott's (ABT) TBI blood test result complements CT scans to help evaluate whether a suspected patient has a TBI.

Phirbo (PAHC) Nutritional Specialty Aids Growth, Low ASP Ails

Phirbo's (PAHC) net vaccine sales remain robust on higher international demand for poultry vaccines.

Hologic (HOLX) Hits a New 52-Week High: What's Driving It?

Investors are optimistic about Hologic's (HOLX) impressive preliminary results for the first quarter of fiscal 2021 and regulatory approvals.

Hologic (HOLX) Rides on Robust Preliminary Q1 Organic Sales

The uptick in Hologic's (HOLX) Diagnostics sales is likely the result of increased demand for COVID-19 testing.

AngioDynamics (ANGO) Q2 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q2.

Hologic (HOLX) to Expand in Oncology With Biotheranostics Buyout

Hologic (HOLX) aims to strengthen its Diagnostics business by foraying into the oncology adjacency space via the acquisition of Biotheranostics.

Walgreens Boots (WBA) Q1 Earnings Top Estimates, Margins Down

Walgreens Boots' (WBA) fiscal first-quarter results reflect overall top-line improvement despite COVID-19-led business disruptions.

Zimmer Biomet (ZBH) Shows Strong APAC Recovery, EMEA Slow

Zimmer Biomet (ZBH) is performing well in its priority areas like quality remediation, supply recovery efforts and product introductions.

Henry Schein (HSIC) Grows Inorganically, Closes JV, Buys Stake

The developments are expected to strengthen Henry Schein's (HSIC) presence in high potential and still-untapped markets.

Hologic (HOLX) Completes SOMATEX Buyout, Expands Portfolio

Hologic (HOLX) to expand biopsy portfolio as well as enhance patient experience via the SOMATEX buyout.